Effectiveness of adalimumab dose escalation, combination therapy of adalimumab with methotrexate, or both in patients with psoriasis in daily practice

Journal of Dermatological Treatment

Volumn 24, Issue 5, 2013, Pages 361-368

  Van Den Reek, Juul MPA ^a   Van Lümig, Paula PM ^a   Kievit, Wietske ^a   Zweegers, Jeffrey ^a   Van De Kerkhof, Peter CM ^a   Seyger, Marieke M ^a   Jong, Elke M D ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Anti psoriatic drugs; Biologics; Combination therapy; Psoriasis; Registry; TNF alpha antagonists; Treatment

Indexed keywords

ADALIMUMAB; METHOTREXATE;

ADD ON THERAPY; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL PRACTICE; CLINICAL TRIAL; COHORT ANALYSIS; COMBINATION CHEMOTHERAPY; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG EFFICACY; FEMALE; HUMAN; MALE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSORIASIS; SCORING SYSTEM; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; COHORT STUDIES; DERMATOLOGIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; PROSPECTIVE STUDIES; PSORIASIS; TREATMENT OUTCOME;

EID: 84880807215     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.3109/09546634.2012.751483     Document Type: Article

References (17)

1. Menter A, Tyring SK, Gordon K, Kimball AB, Leonardi CL, Langley RG, et al. Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. J Am Acad Dermatol. 2008;58:106-115
2. Mrowietz U. Implementing treatment goals for successful long-term management of psoriasis. J Eur Acad Dermatol Venereol. 2012;26:12-20
3. Mrowietz U, Kragballe K, Reich K, Spuls P, Griffiths CE, Nast A, et al. Definition of treatment goals for moderate to severe psoriasis: A European consensus. Arch Dermatol Res. 2011;303:1-10
4. Leonardi C, Sobell JM, Crowley JJ, Mrowietz U, Bao Y, Mulani PM, et al. Efficacy, safety, and medication cost implications of adalimumab 40 mg weekly dosing in psoriasis patients with suboptimal response to 40 mg every other week dosing: Results from an open-label study. Br J Dermatol. 2012;167:658-667
5. Blom M, Kievit W, Kuper HH, Jansen TL, Visser H, den Broeder AA, et al. Frequency and effectiveness of dose increase of adalimumab, etanercept, and infliximab in daily clinical practice. Arthritis Care Res (Hoboken). 2010;62:1335-1341
6. Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, et al. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 2006;54:26-37
7. Gladman DD, Mease PJ, Ritchlin CT, Choy EH, Sharp JT, Ory PA, et al. Adalimumab for long-term treatment of psoriatic arthritis: Forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial. Arthritis Rheum. 2007;56:476-488
8. Heiberg MS, Rodevand E, Mikkelsen K, Kaufmann C, Didriksen A, Mowinckel P, et al. Adalimumab and methotrexate is more effective than adalimumab alone in patients with established rheumatoid arthritis: Results from a 6-month longitudinal, observational, multicentre study. Ann Rheum Dis. 2006;65:1379-1383
9. Mease PJ, Gladman DD, Ritchlin CT, Ruderman EM, Steinfeld SD, Choy EH, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: Results of a doubleblind, randomized, placebo-controlled trial. Arthritis Rheum. 2005;52: 3279-3289
10. Krieckaert CL, Bartelds GM, Lems WF, Wolbink GJ. The effect of immunomodulators on the immunogenicity of TNF-blocking therapeutic monoclonal antibodies: A review. Arthritis Res Ther. 2010;12:217
11. Krieckaert CL, Nurmohamed MT, Wolbink GJ. Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent manner. Ann Rheum Dis. 2012;71: 1914-1915
12. Navarro-Sarabia F, Ariza-Ariza R, Hernandez-Cruz B, Villanueva I. Adalimumab for treating rheumatoid arthritis. Cochrane Database Syst Rev. 2005;CD005113
13. Driessen RJ, van De Kerkhof PC, De Jong EM. Etanercept combined with methotrexate for high-need psoriasis. Br J Dermatol. 2008;159: 460-463
14. Gottlieb AB, Langley RG, Strober BE, Papp KA, Klekotka P, Creamer K, et al. A Randomized, double-blind, placebo-controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasis. Br J Dermatol. 2012;167:649-657
15. Philipp S, Wilsmann-Theis D, Weyergraf A, Rotterdam S, Frambach Y, Gerdes S, et al. Combination of adalimumab with traditional systemic antipsoriatic drugs - A report of 39 cases. J Dtsch Dermatol Ges. 2012;10:821-837
16. van Lumig PP, Driessen RJ, Kievit W, Boezeman JB, van De Kerkhof PC, De Jong EM. Results of three analytical approaches on long-term efficacy of etanercept for psoriasis in daily practice. J Am Acad Dermatol. 2012; Epub ahead of print.
17. Kievit W, Fransen J, Oerlemans AJ, Kuper HH, van der Laar MA, de Rooij DJ, et al. The efficacy of anti-TNF in rheumatoid arthritis, a comparison between randomised controlled trials and clinical practice. Ann Rheum Dis. 2007;66:1473-1478